Identifying chelators for metalloprotein inhibitors using a fragment-based approach.

Fragment-based lead design (FBLD) has been used to identify new metal-binding groups for metalloenzyme inhibitors. When screened at 1 mM, a chelator fragment library (CFL-1.1) of 96 compounds produced hit rates ranging from 29% to 43% for five matrix metalloproteases (MMPs), 24% for anthrax lethal factor (LF), 49% for 5-lipoxygenase (5-LO), and 60% for tyrosinase (TY). The ligand efficiencies (LE) of the fragment hits are excellent, in the range of 0.4-0.8 kcal/mol. The MMP enzymes all generally elicit the same chelators as hits from CFL-1.1; however, the chelator fragments that inhibit structurally unrelated metalloenzymes (LF, 5-LO, TY) vary considerably. To develop more advanced hits, one hit from CFL-1.1, 8-hydroxyquinoline, was elaborated at four different positions around the ring system to generate new fragments. 8-Hydroxyquinoline fragments substituted at either the 5- or 7-positions gave potent hits against MMP-2, with IC(50) values in the low micromolar range. The 8-hydroxyquinoline represents a promising new chelator scaffold for the development of MMP inhibitors that was discovered by use of a metalloprotein-focused chelator fragment library.

[1]  Andrew J. Woodhead,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[2]  Hwan-Suck Chung,et al.  Naturally occurring tyrosinase inhibitors: mechanism and applications in skin health, cosmetics and agriculture industries , 2007, Phytotherapy research : PTR.

[3]  R. Sindelar,et al.  Hydroxamic acids as pharmacological agents. , 2002, Current medicinal chemistry.

[4]  Sina Bavari,et al.  The evolving field of biodefence: therapeutic developments and diagnostics , 2005, Nature Reviews Drug Discovery.

[5]  M. Giorgi,et al.  Binding of 2-hydroxypyridine-N-oxide on dicopper(II) centers: insights into tyrosinase inhibition mechanism by transition-state analogs. , 2009, Inorganic chemistry.

[6]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[7]  M. Suresh,et al.  Synthesis of celecoxib analogues possessing a N-difluoromethyl-1,2-dihydropyrid-2-one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity. , 2009, Journal of medicinal chemistry.

[8]  Seth M. Cohen,et al.  A Macrophage Cell Model for Selective Metalloproteinase Inhibitor Design , 2008, Chembiochem : a European journal of chemical biology.

[9]  Development of integrase inhibitors for treatment of AIDS: an overview. , 2007, European journal of medicinal chemistry.

[10]  A. Strongin,et al.  Anthrax lethal factor protease inhibitors: synthesis, SAR, and structure-based 3D QSAR studies. , 2006, Journal of medicinal chemistry.

[11]  Richard H. Henchman,et al.  From model complexes to metalloprotein inhibition: a synergistic approach to structure-based drug discovery. , 2003, Angewandte Chemie.

[12]  L. Kotra,et al.  Structural insight into the binding motifs for the calcium ion and the non-catalytic zinc in matrix metalloproteases. , 1998, Bioorganic & medicinal chemistry letters.

[13]  Seth M. Cohen,et al.  New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups. , 2004, Journal of the American Chemical Society.

[14]  J Andrew McCammon,et al.  Potent, selective pyrone-based inhibitors of stromelysin-1. , 2005, Journal of the American Chemical Society.

[15]  Andrew R Leach,et al.  Fragment screening: an introduction. , 2006, Molecular bioSystems.

[16]  Raphael Nudelman,et al.  Drug Insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis , 2008, Nature Clinical Practice Rheumatology.

[17]  Synthesis and biological evaluation of 1-(benzenesulfonamido)-2-[5-(N-hydroxypyridin-2(1H)-one)]acetylene regioisomers: a novel class of 5-lipoxygenase inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[18]  Seth M. Cohen,et al.  Examination of novel zinc-binding groups for use in matrix metalloproteinase inhibitors. , 2003, Inorganic chemistry.

[19]  C. Supuran,et al.  Design of zinc binding functions for carbonic anhydrase inhibitors. , 2008, Current pharmaceutical design.

[20]  Seth M. Cohen,et al.  Addressing lead toxicity: complexation of lead(II) with thiopyrone and hydroxypyridinethione O,S mixed chelators. , 2004, Inorganic chemistry.

[21]  Seth M. Cohen,et al.  A bioinorganic perspective on matrix metalloproteinase inhibition. , 2004, Current topics in medicinal chemistry.

[22]  S. Yao,et al.  In situ "click" assembly of small molecule matrix metalloprotease inhibitors containing zinc-chelating groups. , 2008, Organic letters.

[23]  Susanne Nyström,et al.  Identification of MMP-12 inhibitors by using biosensor-based screening of a fragment library. , 2008, Journal of medicinal chemistry.

[24]  Seth M. Cohen,et al.  Efficient synthesis of 5-amido-3-hydroxy-4-pyrones as inhibitors of matrix metalloproteinases. , 2007, Organic letters.

[25]  Seth M. Cohen,et al.  Evaluation and Binding‐Mode Prediction of Thiopyrone‐Based Inhibitors of Anthrax Lethal Factor , 2006, ChemMedChem.

[26]  Karl Edman,et al.  Novel prostaglandin D synthase inhibitors generated by fragment-based drug design. , 2008, Journal of medicinal chemistry.

[27]  Takayoshi Suzuki,et al.  Rational design of non-hydroxamate histone deacetylase inhibitors. , 2006, Mini reviews in medicinal chemistry.

[28]  Y. Wan,et al.  1-(1-Arylethylidene)thiosemicarbazide derivatives: a new class of tyrosinase inhibitors. , 2008, Bioorganic & medicinal chemistry.

[29]  R. Hider,et al.  Synthesis of 2-amido-3-hydroxypyridin-4(1H)-ones: novel iron chelators with enhanced pFe3+ values. , 2001, Bioorganic & medicinal chemistry.

[30]  Petra Schneider,et al.  Scaffold‐Hopping Cascade Yields Potent Inhibitors of 5‐Lipoxygenase , 2008, ChemMedChem.

[31]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[32]  M. Uttamchandani,et al.  Rapid assembly of matrix metalloprotease inhibitors using click chemistry. , 2006, Organic letters.

[33]  W. Denny,et al.  Synthesis and evaluation of stable bidentate transition metal complexes of 1-(chloromethyl)-5-hydroxy-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (seco-6-azaCBI-TMI) as hypoxia selective cytotoxins. , 2009, Journal of medicinal chemistry.

[34]  Maria João Ramos,et al.  Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem. , 2008, Current medicinal chemistry.

[35]  P. Margolis,et al.  Targeting metalloenzymes: a strategy that works. , 2003, Current opinion in pharmacology.

[36]  P. Sampson,et al.  Methionine in and out of proteins: targets for drug design. , 2002, Current medicinal chemistry.

[37]  N. Smit,et al.  The Hunt for Natural Skin Whitening Agents , 2009, International journal of molecular sciences.

[38]  R. Hider,et al.  Synthesis, physicochemical characterization, and biological evaluation of 2-(1'-hydroxyalkyl)-3-hydroxypyridin-4-ones: novel iron chelators with enhanced pFe(3+) values. , 1999, Journal of medicinal chemistry.

[39]  Seth M. Cohen,et al.  From Sensors to Silencers: Quinoline- and Benzimidazole-Sulfonamides as Inhibitors for Zinc Proteases , 2010, Journal of the American Chemical Society.

[40]  R. Hider,et al.  The inhibition of tyrosinase by pyridinones. , 1989, The Biochemical journal.

[41]  L. Wackett,et al.  Atrazine chlorohydrolase from Pseudomonas sp. strain ADP is a metalloenzyme. , 2002, Biochemistry.

[42]  P. Ascenzi,et al.  Structural bases for substrate and inhibitor recognition by matrix metalloproteinases. , 2008, Current medicinal chemistry.

[43]  D. Hupe,et al.  A Rationalization of the Acidic pH Dependence for Stromelysin-1 (Matrix Metalloproteinase-3) Catalysis and Inhibition* , 2000, The Journal of Biological Chemistry.

[44]  Seth M. Cohen,et al.  Elucidating drug-metalloprotein interactions with tris(pyrazolyl)borate model complexes. , 2002, Inorganic chemistry.

[45]  Yan Guo,et al.  NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability. , 2002, Journal of medicinal chemistry.

[46]  R. Bhatnagar,et al.  Anthrax Toxin , 2001, Critical reviews in microbiology.

[47]  D. Hazuda,et al.  Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. , 2008, Journal of medicinal chemistry.

[48]  Lewis C Cantley,et al.  The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor , 2004, Nature Structural &Molecular Biology.

[49]  Seth M. Cohen,et al.  Heterocyclic zinc-binding groups for use in next-generation matrix metalloproteinase inhibitors: potency, toxicity, and reactivity , 2006, JBIC Journal of Biological Inorganic Chemistry.

[50]  F. García-Carmona,et al.  4-Substituted resorcinols (sulfite alternatives) as slow-binding inhibitors of tyrosinase catecholase activity , 1997 .

[51]  F. Leroux,et al.  Synthesis of a 200-member library of squaric acid N-hydroxylamide amides. , 2008, Bioorganic & medicinal chemistry letters.

[52]  Yuchen Cao,et al.  Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship. , 2009, Bioorganic & medicinal chemistry letters.

[53]  Seth M. Cohen,et al.  Metal complexes of the trans-influencing ligand thiomaltol. , 2003, Inorganic chemistry.

[54]  J H Musser,et al.  Synthesis and antiallergic activities of 1,3-oxazolo[4,5-h]quinolines. , 1985, Journal of medicinal chemistry.

[55]  Jean M. Severin,et al.  Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR , 1997 .

[56]  A. Gearing,et al.  Design and therapeutic application of matrix metalloproteinase inhibitors. , 1999, Chemical reviews.

[57]  P. Dunkel,et al.  Semicarbazide-sensitive amine oxidase/vascular adhesion protein 1: recent developments concerning substrates and inhibitors of a promising therapeutic target. , 2008, Current medicinal chemistry.

[58]  Y. Yen,et al.  Ribonucleotide reductase inhibitors and future drug design. , 2006, Current cancer drug targets.

[59]  Seth M Cohen,et al.  Zinc‐Binding Groups Modulate Selective Inhibition of MMPs , 2008, ChemMedChem.

[60]  E. Sturrock,et al.  Inhibition of zinc metallopeptidases in cardiovascular disease--from unity to trinity, or duality? , 2009, Current pharmaceutical design.

[61]  L. Bastide,et al.  Progress in targeting bacterial transcription. , 2007, Drug discovery today.

[62]  D Job,et al.  The crystal structure of plant acetohydroxy acid isomeroreductase complexed with NADPH, two magnesium ions and a herbicidal transition state analog determined at 1.65 Å resolution , 1997, The EMBO journal.

[63]  S. Meroueh,et al.  Quest for selectivity in inhibition of matrix metalloproteinases. , 2004, Current topics in medicinal chemistry.

[64]  A. Mai,et al.  Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise. , 2009, Current pharmaceutical design.

[65]  C. H. Jarboe,et al.  2-Pyrones. XIX. 3-Hydroxy-2-pyrone1 and 4-Arylhydrazono-2,3-pyranones , 1956 .

[66]  Seth M Cohen,et al.  A new role for old ligands: discerning chelators for zinc metalloproteinases. , 2006, Journal of the American Chemical Society.

[67]  Seth M Cohen,et al.  To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition. , 2010, Biochimica et biophysica acta.

[68]  Yi Lu,et al.  Metalloprotein and metallo-DNA/RNAzyme design: current approaches, success measures, and future challenges. , 2006, Inorganic chemistry.

[69]  M. Pellecchia,et al.  Structure-activity relationship studies of a novel series of anthrax lethal factor inhibitors. , 2009, Bioorganic & medicinal chemistry.

[70]  A. Gearing,et al.  Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors , 1999 .

[71]  C. Fierke,et al.  Zinc hydrolases: the mechanisms of zinc-dependent deacetylases. , 2005, Archives of biochemistry and biophysics.

[72]  Seth M. Cohen,et al.  Chelator Fragment Libraries for Targeting Metalloproteinases , 2010, ChemMedChem.

[73]  G. Cristalli,et al.  Adenosine deaminase: Functional implications and different classes of inhibitors , 2001, Medicinal research reviews.